ID   NCI-H2591
AC   CVCL_A543
SY   H2591; H-2591; NCIH2591
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471042
DR   cancercelllines; CVCL_A543
DR   Cell_Model_Passport; SIDM00101
DR   Cosmic; 1032379
DR   Cosmic-CLP; 1240131
DR   DepMap; ACH-002126
DR   EGA; EGAS00001000978
DR   GDSC; 1240131
DR   GEO; GSM1669821
DR   PharmacoDB; H2591_423_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54907986
RX   PubMed=7695406;
RX   PubMed=8806092;
RX   PubMed=11030152;
RX   PubMed=23830731;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0.61%; South Asian=1.63%; European, North=68.64%; European, South=29.11% (PubMed=30894373).
CC   Derived from site: In situ; Lung, pleura; UBERON=UBERON_0000977.
ST   Source(s): Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10,14
ST   D13S317: 12
ST   D16S539: 10,12
ST   D18S51: 12
ST   D21S11: 30,32.2
ST   D3S1358: 18
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   D8S1179: 8,14
ST   FGA: 19,22
ST   Penta D: 12
ST   Penta E: 5,10
ST   TH01: 8
ST   TPOX: 8,12
ST   vWA: 16,17
DI   NCIt; C45662; Pleural epithelioid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=7695406; DOI=10.1016/0003-4975(95)00045-M;
RA   Pass H.I., Stevens E.J., Oie H.K., Tsokos M.G., Abati A.D., Fetsch P.A.,
RA   Mew D.J.Y., Pogrebniak H.W., Matthews W.J.;
RT   "Characteristics of nine newly derived mesothelioma cell lines.";
RL   Ann. Thorac. Surg. 59:835-844(1995).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=23830731; DOI=10.1016/j.cancergen.2013.04.006;
RA   Klorin G., Rozenblum E., Glebov O.K., Walker R.L., Park Y.,
RA   Meltzer P.S., Kirsch I.R., Kaye F.J., Roschke A.V.;
RT   "Integrated high-resolution array CGH and SKY analysis of homozygous
RT   deletions and other genomic alterations present in malignant
RT   mesothelioma cell lines.";
RL   Cancer Genet. 206:191-205(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//